Copyright © 2024 Research Nester. All Rights Reserved
Attenuated Familial Adenomatous Polyposis Treatment Market size is likely to expand at significant growth rate during the forecast period i.e., between 2024-2036. The growth of the market can be attributed to the growing number of incidences of colorectal diseases, inheritance of adenomatous polyposis coli (APC) gene and history of AFAP in someone’s family. It is calculated that the United States alone will have approximately 105,000 new cases of colon cancer and more than 45, 000 cases of rectal cancer by the end of 2021. Apart from these, growing technological advancements for developing effective treatment for the disease in developed nations and increasing prevalence of familial adenomatous polyposis (FAP) are also expected to drive growth to the market in the upcoming years. Furthermore, change in dietary preference, unhealthy lifestyle changes and lack of physical activities are projected to offer lucrative opportunities to the attenuated familial adenomatous polyposis treatment market in the near future.
Growth Drivers
Challenges
|
2023 |
|
|
Forecast Year |
2024–2036 |
|
Regional Scope |
|
The attenuated familial adenomatous polyposis treatment market is segmented by drug class into cox-2 inhibitors, nonsteroidal anti-inflammatory drugs, and others, out of which, the segment for nonsteroidal anti-inflammatory drugs is anticipated to hold the largest share in the attenuated familial adenomatous polyposis drugs market on account of their effectiveness in relieving pain, reducing inflammation and efficiency in controlling processes such as irregular blood flow and formation of blood clots. Additionally, on the basis of distribution channel, the hospital pharmacy segment is assessed to occupy a larger market share during the forecast period, which can be ascribed to the fact that a hospital facility promotes frequent interactions of prescriber and other health professionals and improved input in making efficient drugs related decisions.
Our in-depth analysis of the global market includes the following segments:
|
Product Type |
|
|
Drug Class |
|
|
Distribution Channel |
|
On the basis of geographical analysis, the attenuated familial adenomatous polyposis treatment market is segmented into five major regions including North America, Europe, Asia Pacific, Latin America and the Middle East & Africa. The market in the North America is estimated to account for largest revenue share by 2036, on the back of strong presence of major market players and high healthcare expenditure. In addition, increasing incidences of FAP in the United States is also expected to boost market growth in the region in the upcoming years. It is evaluated that on an average, every 1 in 7000 to 10,000 persons in the United States is suffering from FAP. In totality, more than 49,000 families in the country are affected by the repercussions of the disease. Moreover, the attenuated familial adenomatous polyposis treatment market in Europe is also estimated to occupy a notable share owing to the rising number of R&D activities in the medical sector and growing investments of key industry players to develop and commercialize their drug candidates in the region.
Author Credits: Radhika Pawar
Copyright © 2024 Research Nester. All Rights Reserved
FREE Sample Copy includes market overview, growth trends, statistical charts & tables, forecast estimates, and much more.
Have questions before ordering this report?